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Background: Millions of people who need treatment for substance use disorders (SUD) do not receive it.
Evidence-based practices for treating SUD exist, and some are appropriate for delivery outside of specialty care
settings. Primary care is an opportune setting in which to deliver SUD treatment because many individuals see
their primary care providers at least once a year. Further, the Patient Protection and Affordable Care Act (PPACA)
increases coverage for SUD treatment and is increasing the number of individuals seeking primary care services.
In this article, we present the protocol for a study testing the effects of an organizational readiness and service
delivery intervention on increasing the uptake of SUD treatment in primary care and on patient outcomes.
Methods/design: In a randomized controlled trial, we test the combined effects of an organizational readiness
intervention consisting of implementation tools and activities and an integrated collaborative care service delivery
intervention based on the Chronic Care Model on service system (patient-centered care, utilization of substance use
disorder treatment, utilization of health care services and adoption and sustainability of evidence-based practices) and
patient (substance use, consequences of use, health and mental health, and satisfaction with care) outcomes. We
also use a repeated measures design to test organizational changes throughout the study, such as acceptability,
appropriateness and feasibility of the practices to providers, and provider intention to adopt the practices. We
use provider focus groups, provider and patient surveys, and administrative data to measure outcomes.
Discussion: The present study responds to critical gaps in health care services for people with substance use
disorders, including the need for greater access to SUD treatment and greater uptake of evidence-based practices
in primary care. We designed a multi-level study that combines implementation tools to increase organizational
readiness to adopt and sustain evidence-based practices (EBPs) and tests the effectiveness of a service delivery
intervention on service system and patient outcomes related to SUD services.
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Substance use disorders (SUD) continue to be under-
identified and under-treated [1]. In 2013, 22.7 million
people aged 12 or older needed treatment for an illicit
drug or alcohol use problem; of these, 20.2 million did not
receive it [1]. The consequences of untreated alcohol and
drug abuse are great and include increased risk of disease,
injury, disability, and death [2,3] as well as hundreds of
billions of dollars in costs to the criminal justice, social
welfare, and health care systems [4-6]. Historically, treat-
ment of SUD has taken place in residential and outpatient
specialty care settings. Although specialty care settings
play an important role for individuals with severe depend-
ence, long waiting lists, stigma, and the lack of public
funding for patients without insurance coverage have con-
tributed to the lack of access. Further, many people who
need treatment are not aware that they need it, are not
ready for treatment, or do not know how or where to seek
treatment [7].
Primary care clinics are a feasible and opportune set-
ting in which to identify and provide treatment to people
with SUD. Studies suggest that the prevalence of alcohol
use disorders and use of illicit drugs is higher among
primary care and emergency room patients than it is in
the general population [8,9]. Further, most individuals
(82%) visit a health professional at least once a year, thus
providing ample opportunity for providers to identify pa-
tients in need of treatment [10]. Research suggests that
integrating SUD treatment and general health care can
result in less utilization of inpatient care and fewer
emergency room visits [11] and that integrated care is
acceptable to patients with an SUD [12].
However, despite the potential benefits of providing
SUD screening and treatment in primary care and the
existence of evidence-based practices (EBP) suitable for
delivery in these settings [13-21], uptake of evidence-
based SUD treatments in primary care has been slow.
Accordingly, patients are unlikely to receive treatment
for their SUD in primary care [20-24]. Some of the
organizational barriers to providing SUD treatment in
primary care settings include lack of insurance reim-
bursement, perceived lack of time to fully assess and dis-
cuss substance use, and lack of administrative buy-in for
integrating SUD care into medical practices [25,26]. At
the physician level, perceived barriers to SUD treatment
adoption include negative attitudes toward people with
SUD, lack of confidence among physicians in their abil-
ity to treat SUDs, lack of adequate role models and ac-
cess to decision support consultants, and deficiencies in
training and expertise in addiction treatment [13,25-28].
Research on introducing new practices into health care
and other organizations suggests that intervention at both
the organizational level (i.e., to increase organizational
readiness to adopt new practices) and service deliverysystem level (i.e., reorganizing how care is provided to
support the new practice) may both be necessary to inte-
grate and sustain EBP [29-31]. Organizational readiness
refers to “the extent to which organizational members are
psychologically and behaviorally prepared to implement
organizational change” [32]. Interventions that increase an
organization’s commitment to change and the ability of
the members of the organization to visualize how the new
practice could be adopted and incorporated into existing
practices are both important to increasing organizational
readiness and adoption of EBP [33]. However, even when
an organization exhibits high organizational readiness,
change may not be successful unless attention is paid to
how the new practice is supported and integrated into
existing care practices. Further, adapting new practices
to fit the nuances of a setting is a key component of
whether the practice is ultimately accepted and adopted.
As Damschroder et al. note, “without adaptation, inter-
ventions usually come to a setting as a poor fit, resisted by
individuals who will be affected by the intervention, and
requiring an active process to engage individuals in order
to accomplish implementation [30].”
To address the need for change at two levels—organi-
zational and service delivery system—to increase the in-
tent and ability of primary care providers to identify and
treat opioid and alcohol use disorders (OAUD), we de-
signed a multi-level study to create and evaluate change
at both levels. We call this study substance use motiv-
ation medication integrated treatment (SUMMIT) and
focus on alcohol and opiate use disorders because of
their relevance to the clinic population and availability
of effective medications. At the organizational level, we
test the effects of an organizational readiness interven-
tion on the organization’s readiness to identify and treat
individuals with opioid and alcohol use disorders. At the
service delivery system level, we use Wagner’s Chronic
Care Model [34] to reorganize and guide how care for
OAUD is provided and supported; we call the service
delivery intervention integrated collaborative care (ICC).
Integrated, collaborative approaches have been success-
ful in improving outcomes for patients experiencing a
variety of different chronic illnesses, including diabetes
[35], asthma [35], and depression [36]. ICC has improved
implementation of evidence-based treatments and quality
of care [37], lowered costs [38], improved patient out-
comes [39-42], and is thought to be feasible for and sus-
tainable in primary care clinics [43]. We test the effects of
the organizational readiness intervention using a repeated
measures pre-post design and the impact of the service
delivery intervention on patient-level outcomes using a
randomized controlled trial (RCT) to compare the service
delivery intervention (ICC) with “service as usual” (SAU)
on service system and patient outcomes. We hypothesize
that provider (providers include administrators, medical
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implement the EBP and patient-centered SUD care will
improve from the pre-organizational readiness interven-
tion period (year 1) to the post-readiness intervention pe-
riods (years 2–5); that patients in the ICC condition will
report more integrated, patient-centered evidence-based
care for their opioid and/or alcohol use disorders, will be
more likely to receive OAUD care, and will have lower
overall health care utilization (e.g., emergency department
and medical visits) than patients in the SAU condition;
and that provider adoption of EBP will increase from year
2 to years 3 and 4 and that providers will still be delivering
OAUD EBP a year after completion of the study in year 5.
We also hypothesize that patients in the ICC condition
will report less substance use, fewer SUD consequences,
higher health and mental health functioning, and greater
satisfaction with their SUD care 6 months after enroll-
ment than SAU patients.
The evidence-based practices that we are introducing
into the clinic are two medications—buprenorphine/na-
loxone (BUP/NX) (trade name Suboxone®) for opioid de-
pendence and extended-release injectable naltrexone
(XR-NTX) (trade name Vivitrol®) for alcohol dependen-
ce—and a motivational interviewing (MI)-based behav-
ioral treatment for those with abuse or dependence of
either substance. BUP/NX has been proven effective for
patients with opioid (heroin as well as prescription opi-
oid) dependence and is feasible for delivery in office-
based settings [12,44-49]; XR-NTX has been found ef-
fective for people with alcohol or opioid dependence
and also is feasible for delivery in primary care [50-54].
Due to greater complexity for administration for opiate
dependence, in this study, XR-NTX is used only to treat
alcohol dependence. MI-based interventions have im-
proved SUD treatment outcomes [18,19,55,56].
In this article, we present our methods, including study
setting; conceptual framework; study design; participant
recruitment; a description of the interventions, which con-
sist of the organizational readiness intervention and the
service delivery intervention; as well as our measures, data
collection procedures, and analysis plan. We conclude
with a discussion of the study’s unique design and its rele-
vance to implementation of OAUD treatment in primary
care, and we note the study’s limitations.
Methods/design
Study setting
We are conducting the study in a large urban, federally
qualified health center (FQHC) in Los Angeles that
serves approximately 20,000 patients annually. The study
is taking place at the FQHC’s two largest sites. We
elected to hold the study in an FQHC because of the ex-
pected influx of patients into publicly funded clinics due
to expanded coverage, an increased funding and anincrease in the number of clinics due to the Patient Pro-
tection and Affordable Care Act (PPACA) [57], and the
greater opportunity to reach more individuals who need
treatment. The clinic currently has integrated mental
health services and provides treatment for anxiety and
depressive disorders; however, prior to the study, the
clinic did not conduct any screening or treatment for
SUD. If substance misuse was identified, patients were
sometimes, but not systematically, referred to specialty
care.
Conceptual framework
In our conceptual framework, illustrated in Figure 1, the
organizational readiness intervention increases provider
readiness to use each of the EBP for OAUD (the two medi-
cations and the MI-based behavioral therapy) as well as
readiness to adopt ICC (the service delivery intervention)
to deliver the three EBP. The organizational readiness
intervention consists of well-studied “implementation”
tools, designed to increase the readiness of an organization
to implement and deliver new practices. Our measures of
organizational readiness are provider acceptability of the
EBP, provider perceptions of EBP appropriateness and
feasibility, and provider intention to adopt each EBP. In
addition, because an aspect of organizational readiness is
the ability of providers to visualize how the new practices
can be adopted and integrated into the existing workflow
[33], a final measure of readiness is the development of lo-
cally tailored EBP protocols and an ICC protocol that
shows how the EBP will fit into clinic workflow.
In the second part of the conceptual framework, the ser-
vice delivery intervention (ICC) facilitates the uptake of
the EBP and affects service system outcomes (e.g., patient-
centered SUD care, measured at the level of the patient
and provider, and service utilization, measured at the level
of the patient) and patient functioning outcomes (e.g.,
substance use, consequences of use, both measured at the
level of the patient). While organizational readiness may
improve immediately following the organizational readi-
ness intervention, we expect that once the three EBP are
implemented through ICC and the staff sees improved pa-
tient outcomes, a feedback loop will occur, leading to even
greater staff acceptance of the new practices.
Study design
The study is designed to test the combined effect of
both an organizational readiness intervention (which in-
cludes a 1-year organizational preparation period and an
8-month pilot of the ICC condition study) and a service
delivery intervention (see Figure 2). We examine the ef-
fects of the interventions on organizational readiness,
service system, and patient outcomes, all of which are
believed to be important in understanding the uptake of
new practices [58]. To test the unique effects of the
Figure 1 SUMMIT conceptual framework for integrating SUD EBP into primary care.
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comes, we use a pre-post-intervention design and meas-
ure these outcomes at the beginning of the study and
then again at the end of year 1. At the end of year 1, we
implement an eight-month pilot test of ICC. During the
pilot test, providers gain experience with the protocols,
and the protocols are iteratively adapted and refined
based on provider feedback. Because we hypothesize that
readiness outcomes may continue to improve as pro-
viders gain experience with ICC and the three treat-
ments, we continue to measure organizational readiness
outcomes annually at years 2–5. Thus, changes in out-
comes between year 1 and years 2–5 reflect the combined
effect of both the organizational readiness intervention
and ICC on provider outcomes. To test the effects of the
interventions on service system and patient-level out-
comes, we are conducting an RCT to compare the effects
of ICC with SAU. Service-system outcomes are patient-
centered collaborative care, utilization of SUD treatment,
patient utilization of health care services, provider adop-
tion of EBP, and sustainability of EBP. Patient-level out-
comes include substance use, consequences of use,physical and mental health functioning, and patient satis-
faction with SUD care.
For the RCT, all patients are screened for drug and al-
cohol use by clinic staff as part of usual care; eligible
consenting patients (i.e., those with risky use or worse)
are referred for further eligibility screening by the re-
search staff, and eligible patients (N = 400) are invited to
participate in the study. After consenting and completing
the baseline interview at one of the study sites, patients
are randomized to the ICC or SAU study condition. We
use a concealed randomization protocol so neither patient
nor research staff is aware of the randomization until after
the baseline interview is completed when research staff
open sequentially numbered envelopes that contain the
randomization assignment. Assignments were made in ad-
vance by a statistician using R software. Patients complete
a follow-up interview by telephone 6 months after the
baseline interview.
The design is a variation of a “hybrid type 2” study,
which Curran et al. [59] describe as the “simultaneous
testing of a clinical intervention and an implementation
intervention/strategy.” In this case, the organizational
Figure 2 SUMMIT study design and timeline.
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tion/strategy and the ICC service delivery intervention is
the clinical intervention. The design, which incorporates
implementation outcomes such as intention to adopt
EBP as well as service system and patient outcomes, fol-
lows the recommendations for implementation research
outcomes suggested by Proctor et al. [58].
Study participants
Organizational readiness intervention
Organizational readiness intervention participants are
full-time clinic administrators, medical and mental healthproviders, and other clinic staff, including medical assis-
tants, discharge coordinators, and front desk and security
staff who agree to participate in interviews, focus groups
and/or surveys (N = 70).
Service delivery intervention
Service delivery intervention participants are full-time
medical and mental health providers (not including resi-
dents) as well as patients who come to the clinic for a
medical visit; the participants initially screen positive for
risky (or worse) alcohol or opioid use using an adapted
NIDA Quick Screen [60] and then meet all study
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(N = 400). To be eligible for the study, patients must be
18 years or older; meet the “Diagnostic and Statistical
Manual of Mental Disorders, fourth edition (DSM IV)”
criteria for abuse of or dependence on alcohol or opioids
(heroin or prescription opioids) (assessed using the WHO
ASSIST [61]); must not have marked functional im-
pairment from bipolar disorder or schizophrenia; speak




To create organizational readiness to provide evidence-
based treatment for OAUD, we employ multiple tools
and activities known to facilitate adoption of EBP as fol-
lows: (1) engaging (and obtaining buy-in from) key ad-
ministrators through regular administrator and board
briefings about the proposed study and how to best pre-
pare the organization to implement the ICC intervention
and providers to adopt the EBP [29,62]; (2) convening
an implementation team that includes key clinical lead-
ership to develop the ICC service delivery intervention
and EBP protocols that fit the clinic [29,63]; (3) selecting
and training physician and therapist champions to serve
as role models for adopting the EBPs [29]; (4) providing
trainings for the staff and providers on the ICC interven-
tion and evidence-based treatment for opioid and
alcohol use disorders [64,65]; and (5) preparing the clinic
environment to identify patients with SUD by instituting
universal screening and brief intervention procedures.
After preparing the organization, we then conduct the
final part of the organizational readiness intervention—
piloting the EBP and ICC protocols and making iterative
adaptations using plan-do-study-act (PDSA) cycles
[66,67]. PDSA cycles offer a structured approach to
engaging staff in making iterative, feedback-based
changes in service delivery [65,66].
Service delivery intervention
We use Wagner’s Chronic Care Model (CCM) [35] as
the theoretical basis for the service delivery intervention
(ICC). The ICC intervention is comprised of five compo-
nents that have been shown to result in improved pa-
tient outcomes; each component supports the delivery
of the planned care for opioid and alcohol use disorders:
(1) redesigning the delivery system to support the deliv-
ery of the EBP and establishing a care coordinator; (2)
modifying clinical information systems to provide alerts
to indicate that patients have problematic substance use
and developing a patient registry used by the care coor-
dinators to monitor and track patients; (3) providing expert
consultation to therapists for complex cases; (4) offering
patients self-management tools; and (5) identifying andestablishing linkages with community resources. These
components are thought to lead to productive patient-
provider interactions, which, in turn, lead to improved ser-
vice system and patient outcomes. The ICC components
are described in greater detail in Additional file 1.
Outcomes, procedures, measures, and analysis plan
Next we describe our data collection procedures, mea-
sures, and analysis plans for the organizational readiness
and service delivery interventions.
Organizational readiness intervention
Procedures We use qualitative and quantitative methods
to study our organizational readiness outcomes as follows:
1) Provider focus groups and semi-structured interviews.
We conduct focus groups with medical and mental health
providers and one-on-one interviews with key administra-
tors to inform the development of our intervention and
EBP protocols and to understand perceptions of accept-
ability, appropriateness, feasibility, and intention to adopt
the ICC and EBP protocols. For both the focus groups
and the interviews, we follow a semi-structured protocol
guide that asks “grand tour” questions related to each do-
main (i.e., general thoughts about ICC and the EBP), and
includes specific probes for more detailed responses. 2)
Provider Surveys. We also conduct surveys in years 1–5
with all the staff and providers to assess changes in
organizational readiness outcomes throughout the study.
The survey includes validated measures as well as “home-
grown” items about specific activities, such as whether
providers prescribed a medication and any barriers to
doing so. Surveys are web-based, or, for providers with less
access to email, through in-person, paper and pencil
surveys.
Measures We measure organizational readiness using
outcomes for implementation research recommended by
Proctor et al. (2011) [58]. We will evaluate the following
outcomes specifically related to our organizational readi-
ness intervention: (1) Acceptability. Acceptability refers
to satisfaction among implementation stakeholders with
the complexity of an EBP or new practice (such as the
ICC intervention) and relative advantage over current
practices [58]. To assess acceptability we adapted items
for the staff survey from Moore and Benbasat’s [68] vali-
dated instrument which maps onto parallel elements of
Roger’s elements of successful diffusion (i.e., complexity,
relative ease of use) [69]. An example of these items is:
Prescribing extended-release injectable naltrexone for pa-
tients with alcohol use disorders at this clinic would be
relatively easy to do. We also include locally developed
items in the survey to capture barriers to use as well as
items from the National Center for Addiction and
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that capture providers’ opinions about the effectiveness
of OAUD EBP, as well whether providers find it difficult
to discuss OAUD with their patients. We ask specific
questions about acceptability in the focus groups and in-
terviews, such as: How easy or difficult would it be for
providers to prescribe and administer extended-release
injectable naltrexone? What are some of the barriers?
What changes would have to be made to make it more
acceptable? (2) Appropriateness. This refers to the “per-
ceived fit, relevance, or compatibility” [58] of the EBP
and ICC intervention in the clinic. We have adapted
items from Moore and Benbasat [68] that measure com-
patibility of EBP and the ICC intervention with the clinic
and with current work style (also an element of Roger’s
diffusion theory) [69]. This includes items such as: I
think the ICC intervention will fit with the way I like to
work. We also include items from the “Substance Abuse
Attitudes Survey (SAAS)” to measure changes in pro-
vider attitudes about people with substance abuse disor-
ders [71]. The focus groups and interviews also capture
reasons why the EBP or ICC intervention may or may
not be perceived as compatible with work style and with
other approaches to managing patients with OAUD or
introducing new practices into the clinic. (3) Intent to
adopt the EBP. We assess intention to adopt EBP in sev-
eral ways. First, we incorporate into the survey the EBP
Attitude Scale (EBPAS). The EBPAS is a brief (15-item),
valid, reliable measure that assesses general attitudes to-
ward adoption of new clinical practices [72]. Next, we
use items from Moore and Bensabet’s scale that measure
elements associated with successful adoption of new
EBP [68]. To measure intention or willingness to adopt,
we use the “demonstrability” scale, which asks questions
such as “I believe I can communicate to others the conse-
quences of using extended release injectable naltrexone.”
Finally, we ask questions in the focus groups and inter-
views about intent to adopt. (4) Feasibility. Feasibility is
the actual fit, utility, and suitability of a program within
an organization: the practicability [58]. We assess feasi-
bility retrospectively by asking participants in focus
groups and interviews whether the EBP and ICC inter-
vention were successfully implemented and whether
poor resources, training, or other barriers impeded use.
We also ask about feasibility in the provider survey
using items from CASA’s National Survey of Primary
Care Physicians and Patients on Substance Abuse that
capture how prepared providers feel they are to treat pa-
tients with SUD [70]. (5) Adapted EBP and intervention
protocols. Our final measure of readiness is finalized,
adapted protocols for each of the three EBP and the ICC
service delivery intervention, which describe how the
EBP fit into the clinic workflow. Adapted, finalizedprotocols are key to ensuring that staff can visualize how
the EBP and ICC intervention will be implemented.
Analysis plan The semi-structured interview and focus
group data will be analyzed to identify key facilitators
and barriers to implementation using classic content
analyses. Our quantitative analysis of survey items will
consist of pre-post, one-way repeated measures ANOVA
comparisons of survey responses between pre- and all
post-intervention periods.
Service delivery intervention
To examine the effect of our service delivery interven-
tion, we examine service system and patient functioning
outcomes.
Procedures We use a combination of administrative re-
cords, patient interviews and staff surveys to evaluate
service system and patient outcomes, as follows: 1) Ad-
ministrative records. We collect three administrative files
every 6 months—appointments (all appointments sched-
uled whether or not they were kept), encounters (includ-
ing medical and therapy visit reasons and diagnoses),
and medication orders. 2) Patient interviews. The patient
interview contains an assessment of SUD diagnoses, sub-
stance use frequency and quantity, consequences related
to use, and health and mental health functioning items.
We administer patient interviews at baseline and 6 months
after enrollment. 3) Staff surveys. Staff surveys are de-
scribed above.
Service system measures We are analyzing five service
system outcomes: (1) Patient-centered, collaborative SUD
care. We measure patient experiences using a locally de-
veloped measure based on the validated Patient Assess-
ment of Chronic Illness Care (PACIC) [73]. Provider
perceptions of collaborative SUD care are measured using
the Assessment of Chronic Illness Care (ACIC) [74]. (2)
Patient utilization of SUD services. This refers to patient
linkage to and usage of appropriate treatment. We meas-
ure this by examining clinic administrative records that
capture all patient encounter dates, types and providers,
and by patient self-report of clinic services on the follow-
up survey. (3) Patient utilization of health care services.
This refers to utilization of emergency department and
health care services. We measure this by examining clinic
administrative records of clinic health care visits and by
patient self-report of emergency department visits. (4)
Provider adoption of EBP. This is a measure of provider
use of the EBP (either of the medications or the brief
therapy). Although adoption is sometimes thought of as
an implementation (or readiness) outcome, we include it
with service system outcomes because we believe that
both interventions—organizational readiness and service
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adoption by examining administrative records for pre-
scription of either medication or use of the therapy and by
asking providers to self-report use of the EBP in the sur-
vey. (5) Sustainability of EBP. This is the extent to which
the three EBP are still being utilized during year 5 of the
study. Following the end of patient enrollment in the
RCT, we will continue to monitor clinic practices to
examine whether the EBPs are still being utilized following
the end of the RCT.
Patient outcomes We are examining four primary pa-
tient outcomes. Patient outcomes are: (1) Changes in
quantity and frequency of substance use. We measure
this using the Timeline Follow-Back (TFLB), a validated
instrument that uses a calendar to facilitate recall of sub-
stance use over the past 30 days [75]. (2) Consequences
of substance use. To assess consequences, we use the
Shortened Inventory of Problems Alcohol and Drugs
(SIP-AD), a validated instrument that assesses conse-
quences related to substance use in the past 90 days
[76]. (3) Functioning. We assess overall health function-
ing with the SF12 version 2, four-week recall [77]. We
use the Patient Health Questionnaire-9 (PHQ-9) [78] to
assess depressive symptoms and the generalized anxiety
disorder (GAD) [79] to assess symptoms of anxiety. (4)
Satisfaction with SUD care. We use an adapted stan-
dardized patient satisfaction survey [80] to assess patient
satisfaction with SUD services at the clinic.
Analysis plan Our quantitative analysis of provider sur-
vey items and administrative data related to service sys-
tem outcomes will consist of pre-post, one-way repeated
measures ANOVA comparisons of survey responses be-
tween pre- and all post-intervention periods. To analyze
patient-level outcomes, we use an intent-to-treat ap-
proach. We will first conduct a bivariate analysis to esti-
mate the uncontrolled association between being in the
ICC group and outcome. In addition, even though our
design randomly assigns patients, we will assess any pos-
sible imbalance in covariates between ICC and SAU
groups including age, gender, race/ethnicity, and educa-
tion that affect the impact of the ICC intervention on
the outcomes. In cases where observed imbalances are
attributable to sample attrition, we will correct for po-
tential bias due to attrition at follow-up using response
weights. In addition, characteristics related to an out-
come at a conservative significance level of α = 0.2 will
be considered covariates in a multivariate analysis for re-
duction of bias if imbalanced or for efficiency gains. For
the multivariate analyses, we will infer about the impact
of ICC on an outcome by fitting hierarchical models
using SAS Proc Mixed, R LME4, and Winbugs. These
models take into account the multi-level structure of thedata: two repeated measures over time (baseline and
6 months) nested within patient and patients nested
within clinics. Sensitivity analyses will be conducted test-
ing model functional forms, the covariates to be used,
and the impact of influential outliers in the analyses re-
sults. For outcomes assessed only at month 6 (e.g., treat-
ment satisfaction), we will use cross-sectional analyses
(such as linear and logistic regression) to estimate the ef-
fect of ICC relative to SAU. This study was designed to
estimate sufficient effect sizes that can be detected with
a power of at least 80% when comparing the outcomes
of patients randomly assigned to the two conditions in
an end-status analysis at month 6 for a 5% significance
level. For continuous outcomes, the study will be able to
detect effect sizes of about 0.30–0.32 standard devia-
tions. These are the kind of effects that can be expected
for an intervention like ICC [42]. For dichotomous out-
comes, we will be able to detect a difference of 13–14
percentage points under the assumption that the SAU
group has a 15% rate of receiving the outcome.
Trial status
The RCT is currently in month 11 of 18 planned months
of active enrollment and data collection.
Discussion
The present study responds to several critical gaps in
health care services for people with SUD—the need for
greater access to SUD treatment, the need for more evi-
dence to support the growing emphasis on collaborative,
integrated care for SUD in primary care settings, and the
call for broader dissemination and adoption of evidence-
based treatments for SUD in general and in medical set-
tings in particular. To meet these diverse and complex
needs, we designed a multi-level study that (1) combines
well-studied implementation tools into an intervention
to increase organizational readiness to adopt and sustain
SUD EBPs in primary care and (2) tests the effectiveness
of a service delivery intervention (ICC) on service sys-
tem and patient outcomes related to SUD services.
Our hybrid type 2 design [59] allows us to support and
study important organizational changes thought to be
critical for the adoption and sustainability of new prac-
tices and to add what we believe is a necessary compo-
nent of integrating SUD EBP into primary care—a
service delivery intervention tailored to meet clinic spec-
ifications and the complex needs of patients with SUD
treated in these settings. The study’s unique design takes
into account the complexity of introducing new EBPs
into a clinical setting, the barriers to integrating SUD
EBP into primary care, and the chronic nature of SUD
and the corresponding complex needs of SUD patients.
We believe that our 18-month organizational readiness
phase, starting with preparing the organization for SUD
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that the ICC intervention (i.e., service delivery system
intervention) and EBP protocols fit the environment will
ensure greater organizational readiness and thus greater
likelihood of adoption and sustainability. We believe our
multi-level approach—addressing organizational change
plus SUD-specific service delivery—is necessary for
adoption and sustainability of SUD EBP in primary care.
The organizational readiness outcomes will allow us to
assess whether our organizational readiness intervention
improves provider perceptions of and intention to adopt
the EBP while the service delivery intervention will help
determine whether the ICC delivery system improves
quality of care and patient outcomes compared to ser-
vice delivery as usual.
Despite the study’s strengths, there are some limitations.
One limitation is the lack of provider randomization to
test the effects of ICC on provider outcomes. This was de-
termined to be infeasible, due to potential contamination
across study conditions and lack of provider and patient
support for asking patients to switch providers to match
their study condition. Additionally, because we are testing
the combined impact of the organizational readiness inter-
vention with the ICC intervention, we will not be able to
draw conclusions about the unique contribution of either
intervention on EBP implementation, sustainability, or pa-
tient outcomes. Moreover, both the organizational readi-
ness and the ICC interventions are complex, containing
multiple elements. We will be unable to tease apart the
impact of particular elements of the interventions (e.g.,
the effect of the decision support system from the self-
management support) on outcomes. Given the emphasis
on examining two complex interventions simultaneously,
we elected to examine them initially in one FQHC serving
a diverse population in a large metropolitan area in Cali-
fornia. It is important to note that this occurred during a
time of rapid health care reform especially in California, a
state that was an early adopter of Medicaid expansion. We
will not know whether our study results will be applicable
to other FQHCs or in other geographical locations.
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Additional file 1: Integrated collaborative care intervention (ICC).
This file contains a detailed description of the elements of the ICC
intervention.
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